logo

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th - Bright Minds Biosciences ( NASDAQ:DRUG )

  4 weeks ago   
post image
Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on September 25th. The event will feature Epilepsy KOLs to discuss the unmet needs for epilepsy treatment.
Ticker Sentiment Impact
DRUG
Somewhat Bullish
19 %